SUMMARY

(ii)

the International Placing of an aggregate of
to
adjustment and the Over-allotment Option) pursuant to the shelf registration statement on
Form S-3ASR that was filed with the SEC and became effective on May 26, 2017, and the
preliminary prospectus supplement filed with the SEC on July 27, 2018 and the final
prospectus supplement
to be filed with the SEC on or about August 3, 2018 pursuant
thereto, including the documents incorporated by reference therein.

initially 59,696,000 Shares (subject

The Offer Shares will represent approximately 8.55% of the issued share capital of our Company
immediately following the completion of the Global Offering, assuming the Over-allotment Option is
not exercised and no Shares are issued pursuant to our Equity Plans. If the Over-allotment Option is
exercised in full, and no Shares are issued pursuant to our Equity Plans, the Offer Shares will represent
approximately 9.71% of
the issued share capital of our Company immediately following the
completion of the Global Offering and the full exercise of the Over-allotment Option.

On February 8, 2016, our Company completed an initial public offerings of ADSs, each of which
represents 13 ordinary shares in the United States and became listed on the Nasdaq. Our ADSs are
presently trading on the Nasdaq. Our Board is of the view that the net proceeds of approximately
HK$6,476.5 million from the Global Offering after deducting the underwriting commissions and other
estimated offering expenses payable by us, and assuming the initial Offer Price of HK$103.00 per
Share, being the mid-point of the indicative Offer Price range set forth on the cover page of this
prospectus, and assuming the Over-allotment Option is not exercised, the Listing and the Global
Offering will provide us with the necessary funding for us to further develop and commercialize our
lead drug candidates as disclosed in “Business — Our Strategy” in this prospectus.

OFFERING STATISTICS

All statistics of market capitalisation in the following table are based on the assumptions that (i)
the Global Offering has been completed and 65,600,000 new Shares are issued pursuant to the Global
Offering; and (ii) 767,163,184 Shares are issued and outstanding following the completion of the
Global Offering.

Based on an Offer Price of
HK$85.00 per Share, after
a Downward Offer Price

Adjustment of 10%

Based on an Offer
Price of HK$94.40

Based on an Offer
Price of HK$111.60

Market capitalisation of our Shares(1) ............
Unaudited pro forma adjusted net tangible

asset per Share(2)

.....................................

HK$65,208,870,640
HK$20.71 (US$2.64)

HK$72,420,204,570
HK$21.49 (US$2.74)

HK$85,615,411,334
HK$22.91 (US$2.92)

Notes:

(1)

(2)

The calculation of market capitalisation is based on 767,163,184 shares expected to be in issue immediately upon
completion of the Global Offering.

The unaudited pro forma adjusted net tangible asset per Share as at March 31, 2018 is calculated after making the
adjustments referred to in Appendix II and on the basis that the Global Offering had been completed at March 31, 2018.

— 17 —

